Breaking News
Get 45% Off 0
Investors lost 37% by missing this ONE signal 😵
Read now

Top Stock Reports For Eli Lilly, Union Pacific & Lockheed

By Zacks Investment ResearchStock MarketsMar 02, 2020 02:14AM ET
www.investing.com/analysis/top-stock-reports-for-eli-lilly-union-pacific--lockheed-200512580
Top Stock Reports For Eli Lilly, Union Pacific & Lockheed
By Zacks Investment Research   |  Mar 02, 2020 02:14AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
KMB
+1.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LLY
-4.58%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BAYGN
+1.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LMT
+1.17%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
UNP
-0.41%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
+0.61%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Monday, March 2, 2020

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Union Pacific (UNP) and Lockheed Martin (LMT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+10.7% vs. +1.4%). The Zacks analyst expects that in 2020, Lilly’s revenue growth will be driven by higher demand for newer drugs like Trulicity, Jardiance, Taltz, Verzenio, Basaglar, Emgality as well as newly launched Baqsimi and Reyvow.

Lilly’s presence across a wide range of therapeutic areas and a strong diabetes portfolio provide support in the face of generic competition. Lilly is making significant pipeline progress with several positive late-stage data readouts scheduled for 2020. Lilly is also regularly adding promising new pipeline assets through business development deals.

However, generic competition for several drugs including the expected generic entry of Forteo, rising pricing pressure in the United States and price cuts in some international markets are some top-line headwinds expected in 2020.

(You can read the full research report on Eli Lilly here >>>)

Shares of Union Pacific have lost -4.5% over the past year against the Zacks Rail industry’s fall of -0.3%. The Zacks analyst is impressed with Union Pacific's initiatives to reward its shareholders. Since November 2017, the company has raised its quarterly dividend payout five times.

Initiatives to control costs in order to drive the bottom line are also impressive. The company’s operating ratio, which improved 210 basis points (bps) year over year to 60.6% in 2019, is mainly attributable to its cost-cutting efforts. Operating ratio is anticipated to improve further in the days to come.

However, sluggish overall volumes (down 6% in 2019) due to freight-related weakness represent a major headwind. Its escalated debt levels are concerning too. Also, the massive capex might be a spoilsport.

(You can read the full research report on Union Pacific here >>>)

Lockheed Martin’s shares have lost -3.1% over the past three months against the Zacks Aerospace Defense industry’s fall of -13.3%. The Zacks analyst believes that expansionary budgetary provisions made by the current U.S. administration will immensely boost this defense prime's business.

Lockheed Martin, being the largest defense contractor in the world, enjoys strong demand for its high-end military equipment in domestic and international markets. It continues to be a strong cash generator, which helps it take important cash deployment decisions.

However, the company’s higher debt-to-equity ratio shows that the stock is highly leveraged when compared with its industry. Lockheed Martin also faces intense global competition for its broad portfolio of products and services. Furthermore, forced cost reduction initiatives for the F-35 program might hamper its operating results.

(You can read the full research report on Lockheed Martin here >>>)

Other noteworthy reports we are featuring today include Johnson & Johnson (NYSE:JNJ) (JNJ), Bayer (DE:BAYGN) (BAYRY) and Prologis (PLD).

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read
Featured Reports

J&J's (JNJ) Generic Woes Hurt Sales, Pipeline Progress Rapid

J&J is witnessing significant generic headwinds in the Pharma unit. Pipeline progress is rapid, per the Zacks analyst. Several pivotal data readouts and regulatory milestones are expected in 2020.

Bayer's (BAYRY) New Products Drive Sales Amidst Competition

Per the Zacks analyst, Bayer's new products continue to drive top line at the company. Deals and acquisitions also look encouraging. However, competition remains a concern.

Expansion Moves Amid Industry Tailwinds to Aid Prologis (PLD)

Per the Zacks Analyst, Prologis is well poised to grow on acquisitions and developments amid high demand for industrial real estate space.

Kimberly-Clark's (NYSE:KMB) Restructuring Plans to Aid Earnings

Kimberly-Clark expects cost savings of $425-$500 million in 2020, from its FORCE Program and 2018 Global Restructuring Program.

Square (NYSE:SQ) Banks on Solid Momentum Across Seller Ecosystem

Per the Zacks analyst, robust products such as Square Terminal, Cash Card, Square Register and Square Capital are strengthening Square's seller ecosystem, which is driving payment volume growth.

Low Costs, Global Reach Aid BNY Mellon (BK) Amid Lower Rates

Per the Zacks analyst, BNY Mellon's efforts to manage expenses and global diversification will likely aid growth.

Acquisitions Drive Nasdaq (NDAQ) Despite Rise in Expenses

Per the Zacks Analyst, buyouts have helped the company to expand the business, which, in turn, has led to top-line growth. However, elevated expenses continue to weigh on margins.

New Upgrades

Rising Assets and Cost Control Efforts Support Lazard (LAZ)

Per the Zacks analyst, Lazard's investment strategies in equity and fixed income markets might boost assets under management. Also, focus on cost savings will likely enhance its profitability.

Menu Innovation & Unit Expansion Aids Cracker Barrel (CBRL)

Per the Zacks Analyst, enhanced marketing efforts, menu Innovations, seasonal promotions as well as unit growth is likely to benefit the company's top line. Moreover, cost cutting efforts bode well.

Avanos (AVNS) Gains Ground on Core Chronic Care Segment

Avanos has been gaining consistently from its Chronic Care arm. The Zacks Analyst is optimistic about the recent FDA approval for the new 80-Watt COOLIEF Radiofrequency System.

New Downgrades

Weak Demand in China & Forex Woes to Hurt A. O. Smith (AOS)

Per a Zacks analyst, A. O. Smith (AOS) is exposed to risks from unfavorable movements in foreign currencies. Also, lower consumer demand in China is likely to hurt results in first-quarter 2020.

High Operating Costs & Elevated Leverage Ail Tenneco (TEN)

Per the Zacks analyst, increasing SG&A expenses are clipping the margins of the firm and the trend is expected to continue. High debt-to-capital ratio of 79% is also a concern.

Weak European & Chinese Market to Ail Cooper-Standard (CPS)

Per the Zacks analyst, lower industry volumes in the European & Chinese market are likely to dent prospects of the OEM auto supplier, Cooper-Standard. Further, high raw material costs is a concern.


undefined undefined

Union Pacific Corporation (NYSE:UNP): Free Stock Analysis Report

Prologis, Inc. (PLD): Free Stock Analysis Report

Lockheed Martin Corporation (NYSE:LMT): Free Stock Analysis Report

Eli Lilly and Company (NYSE:LLY): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

Original post

Zacks Investment Research

Top Stock Reports For Eli Lilly, Union Pacific & Lockheed
 

Related Articles

Top Stock Reports For Eli Lilly, Union Pacific & Lockheed

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email